Earnings Call Intelligence Subscribe
Home › Call Sheets › BSX › Q3'26
Call sheet · Q3'26

Boston Scientific (BSX)

Q3'26 earnings call · held October 28, 2026 · compared with the Q2'26 call · management-credibility review
9/12
Disclosure score
1 high, 3 medium, 3 low flags
Financial quality
Bottom line
The sleeper story here isn't the cyber incident, it's that Boston Scientific just told you on the call that it can't forecast its own business, after a Q2 guide-down was itself missed in Q3. The obvious headline, 'cyber incident plus EP/Watchman cycle trough,' is real, but the binding constraint is product-launch timing: FerroWave Ultra slipped to early 2028 and Penumbra's close slipped to early 2027, both catalysts the entire 2028 reacceleration thesis depends on. John Monson's own words about needing to rebuild confidence in forecasts is the single most important sentence on this call, more telling than any guidance number. My view changes if Q4 actuals come in within the newly guided -1% to -3% range without another surprise miss, and if FerroWave Ultra and Penumbra timelines hold through the next call without slipping a third time.

The 30-second version

  • The real story isn't the cyber incident, it's that management just told you they can't forecast their own business
  • Headline says '2027 will be the trough' but the binding constraint is EP/Watchman product timing slipping further right
  • China pricing and APAC collapsed from +11% to -1% operationally in a single quarter, and nobody asked about it on the call

What changed this quarter

MetricQ2'26Q3'26Change
Total company organic revenue growth+7.0%+1.5%Decelerated 550bps, missed own 3-5% guide
Adjusted EPS$0.86, +15% YoY$0.73, -3% YoYSwung from beat to miss vs 80-82c guide
Adjusted gross margin70.3%68.0%-230bps sequential, -300bps YoY
Adjusted operating margin28.4%26.5%-190bps sequential
GAAP operating margin21.6%16.1%-550bps, adjusted-to-GAAP gap widens to ~1040bps
Watchman global revenue growth+4%-6%1000bps deceleration in one quarter
Electrophysiology revenue growth+9%-5%1400bps swing; US -8%
Asia Pacific operational growth+11%-1%China pricing collapse, 1200bps deceleration
Neuromodulation revenue growth+12%+13%Quietly accelerating, sleeper positive
Interventional cardiology growth+15%+19%Still the best business, accelerating

Accountability tracked

9 new promises made6 narrative shifts flagged5 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BSX Q3'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.